摘要
目的观察布地奈德/福莫特罗干粉吸入剂对稳定期中度慢性阻塞性肺疾病(COPD)的疗效。方法采用随机分组方法将65例稳定期中度COPD患者随机分为实验组(34例)和对照组(31例),分别给予布地奈德/福莫特罗干粉吸入剂和福莫特罗干粉吸入剂治疗6个月,评估呼吸困难程度、6 min平地步行距离(6-MWD)、第1秒用力呼气容积(FEV1)、生活质量及COPD急性发作次数。疗效分析采用t检验和χ2检验。结果 65例患者均完成6个月随访。治疗组呼吸困难评分、6-MWD、FEV1和生活质量评分等指标均较对照组明显改善(P<0.05)。且急性加重患者的门诊和住院人次较对照组少(P<0.05)。结论布地奈德/福莫特罗干粉吸入剂治疗稳定期中度COPD,能有效抑制病情恶化,改善临床症状,并能提高患者生活质量,值得临床推广使用。
Objective To observe the curative effect of budesonide/formoterol dry powder inhaler in treating the stabi- lization period of moderate chronic obstructive pulmonary disease （COPD）. Methods 65 outpatients with stabilization period of moderate COPD were randomly divided into two groups.The treatment group （34 eases ） was treated by budesonide/formoterol dry powder inhaler and the control group（31 eases） was treated by formoterol dry powder inhaler with a treatment course of 6 months. The dyspneic respiration degree, 6 rain walking distance （6-MWD）, quality of life and the 1st seeond forced expiration volume （FEV 1 ） and times of acute exacerbation of COPD （AECOPD） were evaluated. The curative effect was analyzed by t test and）（2 test. Results All 65 eases aeomplished 6-month follow up. The dyspneic respiration scores, 6-MWD, FEV1 and scores of quality of life in the the treatment group were improved obviously compared with the control group （P〈0.05）. The ease-times of outpatient clinic visiting and hospitalization due to acute exacerbation in the treatment group were lowere than those in the control group（P〈 0.05）. Conclusion Budesonide/formoterot dry powder inhaler in the treatment of stable period of moderate to severe COPD can effectively inhibit the disease progression,improve the elinieal symptoms and increase the patient＇s quality of life, and is worthy of promotion.
出处
《现代医药卫生》
2013年第10期1456-1457,共2页
Journal of Modern Medicine & Health
关键词
布地奈德
投药和剂量
乙醇胺类
投药和剂量
肺疾病
慢性阻塞性
药物疗法
随机对照试验
投药
吸入
药物疗法
联合
治疗结果
福莫特罗
Budesonide/administration ＆ dosage
Ethanolamines/administration ＆ dosage
Pulmonary disease, chronic obstructive/drug therapy
Randomized controlled trial
Administration,inhalation
Drug therapy,combination
Treatment outcome
Formoterol
